ISSN: 2090-8083

Journal Home

Parkinson's Disease Q3 Unclaimed

Hindawi Limited Egypt

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Parkinson's Disease is a journal indexed in SJR in Neuroscience (miscellaneous) and Neurology (clinical) with an H index of 54. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 1170 €. The scope of the journal is focused on parkinson's disease. It has an SJR impact factor of 0,584 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,584.

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Neurology (clinical) (Q3) Neuroscience (miscellaneous) (Q3) Psychiatry and Mental Health (Q3)

Price

1170 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,584

SJR Impact factor

54

H Index

51

Total Docs (Last Year)

193

Total Docs (3 years)

2332

Total Refs

567

Total Cites (3 years)

191

Citable Docs (3 years)

3.04

Cites/Doc (2 years)

45.73

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

IBRO Reports Q3
Brain Sciences Q3
Frontiers in Computational Neuroscience Q3
BMC Neuroscience Q3
Experimental Brain Research Q3

Compare this journals

Aims and Scope

Parkinson's disease

Best articles by citations

Remarkably Few Sputum Cultures from People with Parkinson's Disease during Hospital In-Patient Admission

The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluida-Synuclein Levels in Parkinson's Disease: A Meta-Analysis

Combining a Cognitive Concurrent Task with a Motor or Motor-Cognitive Task: Which Is Better to Differentiate Levels of Affectation in Parkinson's Disease?

Plasma Prolidase Activity and Oxidative Stress in Patients with Parkinson's Disease

Recurrent Falls in People with Parkinson's Disease without Cognitive Impairment: Focusing on Modifiable Risk Factors

Changes to Intermediary Metabolites in Sporadic andLRRK2Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy

Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment

The Effects of Uric Acid, Serum Vitamin D3, and Their Interaction on Parkinson's Disease Severity

Validation of the Persian Translation of the Swallowing Disturbance Questionnaire in Parkinson's Disease Patients

MicroRNAs: Game Changers in the Regulation of a-Synuclein in Parkinson's Disease

Effect of Exercise on Motor and Nonmotor Symptoms of Parkinson's Disease

Deep Brain Stimulation of Hemiparkinsonian Rats with Unipolar and Bipolar Electrodes for up to 6 Weeks: Behavioral Testing of Freely Moving Animals

SHOW MORE ARTICLES

Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease

Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study

Association of aBACE1Gene Polymorphism with Parkinson's Disease in a Norwegian Population

LSVT-BIG Improves UPDRS III Scores at 4 Weeks in Parkinson's Disease Patients with Wearing Off: A Prospective, Open-Label Study

Effectiveness of an Inpatient Movement Disorders Program for Patients with Atypical Parkinsonism

Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease

Clinical Pain and Neuropsychological Functioning in Parkinson's Disease: Are They Related?

Comparing Balance Performance on Force Platform Measures in Individuals with Parkinson's Disease and Healthy Adults

L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain

Cognitive Stimulation for Individuals with Parkinson's Disease Dementia Living in Long-Term Care: Preliminary Data from a Randomized Crossover Pilot Study

Long-Term Mortality Analysis in Parkinson's Disease Treated with Deep Brain Stimulation

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving =2000mg Daily Dose of Levodopa